Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registry

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1150-1155

  Kavanaugh, Arthur ^a   Lee, Susan J ^a,b   Curtis, Jeffrey R ^c   Greenberg, Jeffrey D ^d,e   Kremer, Joel M ^e,f   Soto, Lilian ^g   Etzel, Carol J ^e,h   Cox, Vanessa ^e   Yoshida, Kazuki ^i,j   Reed, George W ^e,k   Solomon, Daniel H ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF CHILE   (Chile)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL DISEASE ACTIVITY INDEX; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; REMISSION; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84933053556     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206435     Document Type: Article

References (30)

1. Furst DE, Keystone EC, Ko AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72 (Suppl):ii2-34.
2. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
5. Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73:595-9.
6. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
7. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18:460-4.
8. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
9. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
10. Van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
11. Van der Maas A, Kievit W, van den Bemt BJF, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
12. Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
13. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012;24:319-26.
14. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
15. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
16. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014;24:17-25.
17. Smolen JS, Fleischmann R, van Vollenhoven R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet 2014;383:321-32.
18. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
19. Van Vollenhoven R, Østergaard M, Leirisalo-Repo M, et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial [abstract]. Arthritis Rheum 2012;64(Suppl 10):4171.
20. Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of tnf-blocker injections (STRASS trial) [Abstract]. Ann Rheum Dis 2013;72(Suppl 3):72.
21. Emery P, Hammoudeh M, Fitzgerald O, et al. Sustained remission with etanercept tapering in rheumatoid arthritis. N Engl J Med 2014;371:1781-92.
22. Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission [abstract]. Arthritis Rheum 2012;64(Suppl 10):S336.
23. Smolen JS, Emery P, Ferraccioli G, et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the certain study [abstract]. Ann Rheum Dis 2012;71(Suppl 3):361.
24. Kremer JM. The Corrona database. Clin Exp Rheumatol 2005;23:S172-7.
25. Hougaard P. Survival models for heterogeneous populations derived from stable distributions. Biometrika 1986;73:387-96.
26. Horne R, Weinman J. Patients' beliefs about prescribed medications and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47: 555-67.
27. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy; discordance between disease activity and patients treatment choices. Arthritis Rheum 2007;56:2135-42.
28. Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol 2013;31(Suppl 78):S19-21.
29. Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologic-free remission study in established rheumatoid arthritis patients ORION study [Abstract]. Ann Rheum Dis 2013;72(Suppl 3):613.
30. Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol 2013;40:1069-73.